Dr Reddy's launches Nitroglycerin sublingual tablets in the US

30 August 2016 | News | By BioSpectrum Bureau

Dr Reddy's Laboratories has announced that it has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat (Nitroglycerin) sublingual tablets in the US market on August 26, 2016, having been approved by the United States Food & Drug Administration (USFDA).

The Nitrostat (Nitroglycerin) sublingual tablet brand had the US sales of approximately $108 Million MAT for the most recent twelve months ending in March 2016 according to IMS Health.

Also read: Global antibody production market to reach $13.28 bn by 2021

Dr Reddy's Nitroglycerin sublingual tablets USP, 0.4 mg is available in bottle count size of 100 and a bundle of 4 bottles of count size 25, Nitroglycerin sublingual tablets USP, 0.3mg is available in bottle count size of 100 and the Nitroglycerin sublingual tablets USP, 0.6mg is available in bottle count size of 100.